Honest abe.

CDK4/6 inhibitors are currently the standard systemic therapy choice for advanced hormone receptor(+), HER2(-) breast cancer based on consistent demonstrations of improvements in disease-free survival. This updated analysis of MONARCH2 reveals, for the first time, a clear translation of these outcomes to an improvement in overall survival—a feat not easy to come by for this disease. As a reminder, the CDK4/6 inhibitor in this phase 3 trial was abemaciclib, and it was compared head to head with placebo in combination with fulvestrant. At this prespecified interim analysis, after over 75% of the number of deaths needed for final analysis have occurred (338 of the planned 441 deaths), the secondary endpoint of median overall survival was improved from 37 → 47 months with the addition of abemaciclib to fulvestrant. Once again, while everyone seemed to benefit, the most pronounced improvements were seen in those with visceral disease and/or endocrine therapy resistance. TBL: CDK4/6 inhibition improves overall survival for women with advanced hormone receptor(+), HER2(-) breast cancer. | Sledge Jr., JAMA Oncol 2019